Partnership Set Up to Address Growing Demand for Self-Administered Therapies
A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.
Swiss-based human-centric CDMO, ten23 health, has entered into a manufacturing collaboration with global medical technology company, BD, to support the commercialization of the BD Libertas wearable injector (1). The partnership, which was announced in a Jan. 20, 2026 press release, will help to address the growing demand for self-administered therapies by providing a scalable, ready-to-use injector platform.
The collaboration agreement will see the BD Libertas wearable injector with a 5 mL or 10 mL BD glass cartridge being supported by ten23 health’s process development, aseptic filling, assembly, and quality control services. As a result of this set up, customers will be able to take advantage of the BD wearable platform and ten23 health’s services when seeking to bring high-volume subcutaneous treatments to the clinic and market.
Additionally, ten23 health’s Line 0 — a robot-assisted pilot non-GMP sterile filling line that the company launched in May 2025 (2) — will be available to customers so that they can test cartridge compatibility, perform stability studies, and optimize filling and stopper setting processes under representative conditions. As Line 0 is a non-GMP pilot line, it is easily accessible and can help to reduce costs usually associated with GMP production.
“Enabling successful patient treatment on behalf of our customers is a key priority for ten23,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, in a company press release (1). “Based on the already successful collaboration of ten23 with BD for the BD iDFill solution (RFID-enabled PFS/containers), we are happy to expand our collaboration to also include BD Libertas Wearable Injector platform Our unique offerings and experiences with a range of devices make ten23 an ideal partner for any SC delivery options.”
The companies’ initial collaboration was announced in October 2024 and was aimed at piloting an RFID-based solution to improve manufacturing process efficiency, and provide traceability of individual units (3). End-to-end RFID-enabled syringe traceability was then demonstrated during CPHI Frankfurt in 2025 to allow attendees to experience a full production cycle to see how it can improve safety, quality, and compliance in injectable drug production (4)
References
ten23 health. ten23 health and BD Partner to Enable Supply Chain Readiness of BD Libertas Wearable Injector as Full-Service Solution. Press Release, Jan. 20, 2026.
ten23 health. ten23 health Kickstarts New Era with Launch of Industry-First Robot-Assisted Pilot Non-GMP Sterile Filling in its Basel Facilities. Press Release, May 12, 2025.
ten23 health. BD and ten23 health Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes. Press Release, Oct. 7, 2024.
ten23 health. BD, ten23 health, and Partners to Demo Fill RFID Syringe Traceability at CPHI Frankfurt. Press Release, Oct. 15, 2025.